Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China.
Institute of Model Animal, Wuhan University, Wuhan, China; Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, China.
J Mol Cell Cardiol. 2022 Feb;163:118-132. doi: 10.1016/j.yjmcc.2021.10.007. Epub 2021 Oct 28.
Vascular disease is the prime determinant to cardiovascular morbidities and mortalities, which comprises the early vascular damage and subsequent cardiovascular events. Non-alcohol Fatty Liver Disease (NAFLD) is a systemic metabolic disorder that drives the progression of vascular disease through complex interactions. Although a causal relationship between NAFLD and cardiovascular disease (CVD) has not been established, a growing number of epidemiological studies have demonstrated an independent association between NAFLD and early vascular disease and subsequent cardiovascular events. In addition, mechanistic studies suggest that NAFLD initiates and accelerates vascular injury by increasing systemic inflammation and oxidative stress, impairing insulin sensitivity and lipid metabolism, and modulating epigenetics, the intestinal flora and hepatic autonomic nervous system; thus, NAFLD is a putative driving force for CVD progression. In this review, we summarize the clinical evidence supporting the association of NAFLD with subclinical vascular disease and cardiovascular events and discuss the potential mechanisms by which NAFLD promotes the progression of vascular disease.
血管疾病是心血管疾病发病率和死亡率的主要决定因素,包括早期血管损伤和随后的心血管事件。非酒精性脂肪性肝病(NAFLD)是一种全身性代谢紊乱疾病,通过复杂的相互作用推动血管疾病的进展。尽管尚未确定 NAFLD 与心血管疾病(CVD)之间存在因果关系,但越来越多的流行病学研究表明,NAFLD 与早期血管疾病和随后的心血管事件之间存在独立关联。此外,机制研究表明,NAFLD 通过增加全身炎症和氧化应激、损害胰岛素敏感性和脂质代谢以及调节表观遗传学、肠道菌群和肝脏自主神经系统,启动和加速血管损伤;因此,NAFLD 是 CVD 进展的一个潜在驱动因素。在这篇综述中,我们总结了支持 NAFLD 与亚临床血管疾病和心血管事件之间关联的临床证据,并讨论了 NAFLD 促进血管疾病进展的潜在机制。